New cancer drug ART6043 enters human trials for advanced tumors
NCT ID NCT05898399
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the main focus is on finding the right dose and seeing if it is safe enough to study further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ART6043 (a DNA polymerase theta inhibitor) and olaparib
What this could lead to
If successful, this could provide a new treatment option for people with advanced or metastatic solid tumors, potentially slowing disease progression.
What could go wrong
This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or safe. Side effects are possible, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Clínico Universitario de Valladolid
RECRUITINGValladolid, Castille and León, 47003, Spain
-
Hospital San Pedro de Alcántara
RECRUITINGCáceres, Extremadura, 10003, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, Madrid, 28041, Spain
-
Hospital Universitario Clínico San Cecilio
RECRUITINGGranada, Andalusia, 18007, Spain
-
Hospital de la Santa Creu i Sant Pau
RECRUITINGBarcelona, Catalonia, 08025, Spain
-
Jefferson University Hospitals - Kimmel Cancer Center
ACTIVE_NOT_RECRUITINGPhiladelphia, Pennsylvania, 17107, United States
-
Mary Crowley Cancer Center - Clinic
COMPLETEDDallas, Texas, 75251, United States
-
Memorial Sloan-Kettering Cancer Center (MSKCC)
ACTIVE_NOT_RECRUITINGNew York, New York, 10065-6800, United States
-
SCRI oncology partners
COMPLETEDNashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics (START) - Midwest
ACTIVE_NOT_RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Stephenson Cancer Center - Oncology
ACTIVE_NOT_RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
The University of Texas - MD Anderson Cancer Center
ACTIVE_NOT_RECRUITINGHouston, Texas, 77030, United States